Sanofi Makes $925M Deal for Diabetes Injection Alternative

Aug 11, 2014


Sanofi has signed a worldwide licensing agreement with MannKind Corp worth up to $925 million for inhaled insulin -- an alternative option to daily injections for diabetics.

The deal gives Sanofi the right to develop and market MannKind's inhaled insulin therapy Afrezza for adults with both type 1 and type 2 diabetes. The companies plan to launch Afrezza in the United States in the first quarter of 2015.

Sanofi, facing patent loss next year on its top-selling insulin Lantus, is exploring novel ways of treating diabetes with the recently-approved Afrezza. While Afrezza acts more rapidly than injectable insulins, it will also carry a boxed warning of the risk of acute bronchospasm in patients with asthma and chronic obstructive pulmonary disease.

California-based MannKind will receive an upfront payment of $150 million with potential further milestone payments of up to $775 million, depending on the drug's commercial success.

Read the Reuters release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments